+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Activity of fourth generation cephalosporins against clinical isolates of Enterobacteriaceae

Activity of fourth generation cephalosporins against clinical isolates of Enterobacteriaceae

Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 107(3): 595-598

Cefpirome and cefepime are a novel group of cephalosporins which contain a positively charged quaternary ammonium at carbon 3 of the dihidrothiazone ring. The antimicrobial agents cefpirome, cefepime, cefotaxime, ceftriaxone, ceftazidime, cefoperazone and imipenem were tested against clinical isolates of Escherichia coli (n = 302) and Klebsiella spp. (n = 62) obtained during september-december 2002 from patients of Galaţi Emergency Hospital. The fourth generation cephalosporins cefpirome and cefepime have similar in vitro activities to the third generation cephalosporins. E. coli showed the comparable resistance rates for all cephalosporins. Against Klebsiella spp. strains cefpirome was less active (35.5% resistance) than cefepime (25.8% resistance). As expected, imipenem had excellent activity (100% susceptibility).

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 048166299

Download citation: RISBibTeXText

PMID: 14756068

Related references

High resistance to fourth-generation cephalosporins among clinical isolates of Enterobacteriaceae producing extended-spectrum β-lactamases isolated in Portugal. International Journal of Antimicrobial Agents 33(2): 184-185, 2009

Third-generation cephalosporins resistance in clinical isolates of Enterobacteriaceae. Microbiologica 9(2): 199-207, 1986

A Novel VIM-Type Metallo-β-Lactamase Variant, VIM-60, with Increased Hydrolyzing Activity against Fourth-Generation Cephalosporins in Pseudomonas aeruginosa Clinical Isolates in Japan. Antimicrobial Agents and ChemoTherapy 63(6):, 2019

In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. Journal of ChemoTherapy 8(Suppl. 2): 57-62, 1996

High rates of antimicrobial co-resistance among Enterobacteriaceae: comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins. Revista Espanola de Quimioterapia 20(2): 216-221, 2007

Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital. International Journal of Antimicrobial Agents 29(1): 34-38, 2007

Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates. New Zealand Medical Journal 95(710): 414-416, 1982

In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. Journal of ChemoTherapy 17(1): 3-24, 2005

In vitro activity of 1st 2nd and 3rd generation cephalosporins against 900 clinical isolates of gram negative bacilli. Abstracts of the Annual Meeting of the American Society for Microbiology 83: A9, 1983

Frequency and epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates susceptible to third-generation cephalosporins or to aztreonam. Medecine et Maladies Infectieuses 44(2): 76-78, 2014

Prevalence and mechanism of resistance to 'third-generation' cephalosporins in clinically relevant isolates of Enterobacteriaceae from 43 hospitals in the UK, 1990-1991. Journal of Antimicrobial ChemoTherapy 39(2): 177-187, 1997

Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. Journal of Antimicrobial ChemoTherapy 67(1): 64-68, 2012

Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers. Diagnostic Microbiology and Infectious Disease 14(4): 361-364, 1991

The clinical potential of fourth-generation cephalosporins. Diagnostic Microbiology and Infectious Disease 31(3): 479-480, 1998

Clinical experience with the fourth generation cephalosporins. Journal of ChemoTherapy 8(Suppl. 2): 91-104, 1996